Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III extension study of Chronocort in congenital adrenal hyperplasia
2015-005448-32Phase 3Unknown
- Sponsor
- Diurnal Group plc
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH), sponsored by Diurnal Group plc. Primary endpoint: Safety of Chronocort over time. Status: unknown.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on 2015-005448-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005448-32.